BRPI0900057A2 - processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos - Google Patents

processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos

Info

Publication number
BRPI0900057A2
BRPI0900057A2 BRPI0900057-7A BRPI0900057A BRPI0900057A2 BR PI0900057 A2 BRPI0900057 A2 BR PI0900057A2 BR PI0900057 A BRPI0900057 A BR PI0900057A BR PI0900057 A2 BRPI0900057 A2 BR PI0900057A2
Authority
BR
Brazil
Prior art keywords
von willebrand
willebrand factor
factor
concentrate
complex
Prior art date
Application number
BRPI0900057-7A
Other languages
English (en)
Inventor
Pere Ristol Debart
Tomas Maria Mercedes Faro
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39316136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0900057(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of BRPI0900057A2 publication Critical patent/BRPI0900057A2/pt
Publication of BRPI0900057B1 publication Critical patent/BRPI0900057B1/pt
Publication of BRPI0900057B8 publication Critical patent/BRPI0900057B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/022—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

PROCESSO PARA A OBTENçãO DE UM CONCENTRADO DE FATOR DE VON WILLEBRAND OU DE UM COMPLEXO DE FATOR VIII/FATOR DE VON WILLEBRAND E USO DOS MESMOS. A presente invenção refere-se a um processo para a preparação de um concentrado de Fator de Von Willebrand ou de um complexo de Fator VIII/Fator de Von Willebrand e uso dos mesmos. O processo é caracterizado pela preparação de uma solução de Fator de Von Willebrand ou de um complexo de Fator VIII/Fator de Von Willebrand que contém VWF e uma concentração de até 12 IU de VWF:RCo/ml e uma razão de Fator de Von Willebrand /Fator VIII de 0,4 ou mais e então prosseguindo-se com a nanofiltração da solução preparada em a) através de um filtro que tem um tamanho de poro menor do que 35 nanometros.
BRPI0900057A 2008-01-08 2009-01-06 processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos BRPI0900057B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200800021 2008-01-08
ES200800021A ES2298096B1 (es) 2008-01-08 2008-01-08 Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.

Publications (3)

Publication Number Publication Date
BRPI0900057A2 true BRPI0900057A2 (pt) 2009-09-22
BRPI0900057B1 BRPI0900057B1 (pt) 2021-03-23
BRPI0900057B8 BRPI0900057B8 (pt) 2021-06-29

Family

ID=39316136

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0900057A BRPI0900057B8 (pt) 2008-01-08 2009-01-06 processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos

Country Status (16)

Country Link
US (2) US8354505B2 (pt)
EP (1) EP2078730B9 (pt)
JP (1) JP4976366B2 (pt)
CN (1) CN101480490B (pt)
AR (1) AR072441A1 (pt)
AT (1) ATE509031T1 (pt)
AU (1) AU2008255137C1 (pt)
BR (1) BRPI0900057B8 (pt)
CA (1) CA2645701C (pt)
CL (1) CL2009000022A1 (pt)
ES (2) ES2298096B1 (pt)
MX (1) MX2008015892A (pt)
NZ (1) NZ573400A (pt)
PL (1) PL2078730T3 (pt)
PT (1) PT2078730E (pt)
RU (1) RU2417096C2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
CN103732244A (zh) * 2011-06-10 2014-04-16 巴克斯特国际公司 通过施用重组vwf治疗凝血疾病
ES2641042T3 (es) 2011-06-24 2017-11-07 Asahi Kasei Kuraray Medical Co., Ltd. Procedimiento para la fabricación de un fármaco proteínico
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
ES2693380T3 (es) * 2013-11-08 2018-12-11 Csl Limited Nuevo método para concentrar el factor de von Willebrand o complejos de este
BR112016026842A2 (pt) * 2014-06-06 2017-12-12 Octapharma Ag preparação compreendendo fator viii e peptídeos de fator de von willebrand
CN104804078B (zh) * 2015-05-05 2019-01-04 广东卫伦生物制药有限公司 人体血清凝血因子ⅷ中的病毒过滤方法
EP3642225A1 (en) 2017-06-23 2020-04-29 Baxalta Incorporated Purification of factor viii subspecies
EP3672644A1 (en) * 2017-08-23 2020-07-01 CSL Behring GmbH Method for virus filtration of von willebrand factor
WO2023017020A1 (en) 2021-08-11 2023-02-16 Grifols Worldwide Operations Limited Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
FR2861395B1 (fr) * 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
RU2256464C1 (ru) * 2004-03-12 2005-07-20 Общество с ограниченной ответственностью "БиоГениус" Способ получения с1-эстеразного ингибитора человека и продукт для использования в медицине
FR2874216B1 (fr) * 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu

Also Published As

Publication number Publication date
AU2008255137C1 (en) 2015-08-27
RU2417096C2 (ru) 2011-04-27
NZ573400A (en) 2010-02-26
ES2363827T3 (es) 2011-08-17
PT2078730E (pt) 2011-07-14
EP2078730B9 (en) 2011-12-21
US20090176709A1 (en) 2009-07-09
CN101480490B (zh) 2013-05-29
CN101480490A (zh) 2009-07-15
ES2298096A1 (es) 2008-05-01
AU2008255137B2 (en) 2011-04-07
AR072441A1 (es) 2010-09-01
JP2009161528A (ja) 2009-07-23
EP2078730B1 (en) 2011-05-11
CL2009000022A1 (es) 2009-11-20
AU2008255137A1 (en) 2009-07-23
RU2008151957A (ru) 2010-07-10
CA2645701C (en) 2013-09-17
ATE509031T1 (de) 2011-05-15
HK1129075A1 (zh) 2009-11-20
US8354505B2 (en) 2013-01-15
ES2298096B1 (es) 2009-01-01
JP4976366B2 (ja) 2012-07-18
EP2078730A1 (en) 2009-07-15
US20110275570A1 (en) 2011-11-10
CA2645701A1 (en) 2009-07-08
PL2078730T3 (pl) 2011-10-31
BRPI0900057B8 (pt) 2021-06-29
MX2008015892A (es) 2009-07-07
BRPI0900057B1 (pt) 2021-03-23

Similar Documents

Publication Publication Date Title
BRPI0900057B8 (pt) processo para a obtenção de um concentrado de fator de von willebrand ou de um complexo de fator viii/fator de von willebrand e uso dos mesmos
BR112015005270A2 (pt) composições compreendendo peg e ascorbato
BR112013025554A2 (pt) método para produção de concentrado de dióxido de titânio
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
BR112014029716A2 (pt) remoção de fenol em processo de recuperação de paraxileno
BR112015010915A2 (pt) conversor catalítico de três vias usando nano-partículas
BR112012015201A2 (pt) processo de concentração de micro-organismo e agente de concentração para uso no mesmo
AR059173A1 (es) Procedimiento para la obtencion de un etanol pobre en agua por deshidratacion con membranas y su empleo como educto en la elaboracion de etbe.
BR112012014791A2 (pt) processo para a preparação de uma peneira molecular contendo cobre com a estrutura de chabazita (cha), peneira molecular contendo cobre, catalisador, uso do catalisador, sistema de tratamento de gás de escapamento, e, método para reduzir seletivamente óxidos de nitrigênio nox.
PT2010014E (pt) Solubilizados de conservantes bem como processo para a sua preparação
PT2499165T (pt) Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas
BRPI0516105A (pt) composições de fator de crescimento derivado de plaqueta e métodos de uso destas
BR112014010704A2 (pt) processo para a preparação de uma dispersão de nanopartículas metálicas, dispersão de nanopartículas metálicas, bem como seu uso
BR112014029754B1 (pt) soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição
BR112015006159A2 (pt) composição de revestimento de nanocelulose, seus usos e método para sua fabricação
AR065963A1 (es) Solucion acuosa de peroxido de hidrogeno, proceso para su preparacion y su uso
BRPI0513503A (pt) composições detergentes compreendendo partìculas coloridas
BRPI0805397A2 (pt) modelo de equipamento de rotina de assento
WO2005025500A3 (en) Process for preparing water soluble diterpenes and their applications
AR072212A1 (es) Una composicion farmaceutica que comprende rebamipida
WO2009115614A3 (en) Von willebrand factor specific binders and methods of use therefor
BRPI0504445A (pt) composição de trombina e processo para a sua preparação
BR112012008666A2 (pt) processo para a preparação de um pó, formulação, e, uso do pó preparado por um processo
PE20130728A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina
BR112017022971A2 (pt) aperfeiçoamentos em ou com relação a compostos orgânicos

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2020 DE 22/09/2009, QUANTO AO ITEM (72)

B25G Requested change of headquarter approved

Owner name: GRIFOLS, S.A. (ES)

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2620 DE 23/03/2021 QUANTO AO ENDERECO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2808 DE 29-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.